RNAPc2 Inhibits colorectal cancer in mice through tissue factor

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 208-216

  Zhao, Jingsong ^b   Aguilar, Gerard ^a   Palencia, Servando ^a   Newton, Elizabeth ^a   Abo, Arie ^a  

^a Nuvelo Inc   (United States)

^b Department of Research Nuvelo ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT PROTEIN; BEVACIZUMAB; FLUOROURACIL; IRINOTECAN; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN CELL; INTESTINE TUMOR; LIVER METASTASIS; LONG TERM CARE; LUNG METASTASIS; MICROVASCULATURE; MOUSE; NONHUMAN; NUDE MOUSE; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HELMINTH PROTEINS; HUMANS; INTESTINAL NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; THROMBOPLASTIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58849160498     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0407     Document Type: Article

References (45)

1. Stassens P, Bergum PW, Gansemans Y, et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci U S A 1996;93: 2149-54.
2. Lee AY, VIasuk GP. Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor Vila/tissue factor. J Intern Med 2003;254:313-21.
3. Bergum PW, Cruikshank A, Maki SL, Kelly CR, Ruf W, Vlasuk GP. Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor Vila-tissue factor complex by recombinant nematode anticoagulant protein c2. J Biol Chem 2001;276:10063-71.
4. Francis JL, Biggerstaff J, Amirkhosravi A, Hemostasis and malignancy. Semin Thromb Hemost 1998;24: 93-109.
5. Zacharski LR, Memoli VA, Costantini V, Wojtukiewicz MZ, Ornstein DL. Clotting factors in tumour tissue: implications for cancer therapy. Blood Coagul Fibrinolysis 1990;1:71 -8.
6. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activation in cancer with high factor Vila and tissue factor. Lancet 1995;346:1004-5.
7. Nakasaki T, Wada H, Shigemori C, et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002;69:247-54.
8. Khorana AA, Ahrendt SA, Ryan CK, et al Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007;13:2870 - 5.
9. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003;124:58-68S.
10. Belting M, Dorrell Ml, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10:502-9.
11. Mueller BM, Reisfeld RA, EdgingtonTS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci US A1992;89:11832-6.
12. Rickles FR, Shoji M, Abe K. The role of the he
13. mostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 2001; 73:145-50.
14. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94: 1320-7.
15. Lykke J, Nielsen HJ, The role of tissue factor in colorectal cancer. Eur J Surg Oncol 2003;29:417-22.
16. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668-70.
17. Mungall D. rNAPc2. Nuvelo. Curr Opin Investig Drugs 2004;5:327-33.
18. Zhao J, Huang L, Belmar N, Buelow R, FongT. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res 2004;10:2851 -9.
19. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
20. Cai SR, Garbow JR, Culverhouse R, et al A mouse model for developing treatment for secondary liver tumors. IntJ Oncol 2005;27:113-20.
21. Moser AR, Dove WF, Roth KA, Gordon Jl. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J Cell Biol 1992;116:1517-26.
22. Boivin GP, Washington K.Yang K, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003;124: 762-77.
23. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005;105:1734-41.
24. Miyamoto S, Nakamura M, Shitara K, et al. Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin Cancer Res 2005; 11:3494-502.
25. Chung DC. The genetic basis of colorectal cancer:insights into critical pathways of tumorigenesis. Gastroenterology 2000;119:854-65.
26. HembroughTA, Swartz GM, Papathanassiu A, et al. Tissue factor/factor Vila inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003;63:2997-3000.
27. Donati MB. Cancerandthrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74:278 - 81.
28. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31.
29. Hoffman R, Haim N, Brenner B. Cancer and thrombosis revisited. Blood Rev 2001;15:61 -7.
30. Kakkar AK, Williamson RC. Antithrombotic therapy in cancer. BMJ 1999:318:1571 -2.
31. Ak EA, Kamath G, Kim SY, et al. Oral anticoagulation may prolong survival of a subgroup of patients with cancer: a Cochrane systematic review. J Exp Clin Cancer Res 2007;26:175-84.
32. Petralia P, Kakkar AK. Antithrombotic therapy with low molecular weight heparin in cancer patients. Eur J Med Res 2004;9:119-24.
33. Esumi N, Fan D, Fidler IJ. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 1991;51:4549-56.
34. Donnelly KM, Bromberg ME, Milstone A, et al. Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro. Thromb Haemost 1998;79: 1041 -7.
35. Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature1996;383:73-5.
36. BuggeTH, Xiao Q, Kombrinck KW, et al Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U S A 1996;93:6258-63.
37. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ, Jr. Targeted disruption of the murine tissue factor gene results in embryonic lethality Blood 1996; 88:1583-7.
38. Belting M, Ahamed J. Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vase Biol 2005;25:1545-50.
39. Amirkhosravi A, MeyerT, Chang JY, et al. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002; 87:930-6.
40. Chand HS, Du X, Ma D, et al. The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice Blood 2004;103:1069-77
41. Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad 0. Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice Eur J Cancer 2004;40:1593-8.
42. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
43. Min/+ mouse model of colon cancer: gene expression profiling in tumors. J Cell Biochem 2004;93:1242-54.
44. Batlle E, Bacani J, Begthel H, et al. EphB receptor activity suppresses colorectal cancer progression. Nature 2005;435:1126-30.
45. Min/+ mice. Cancer Res 2006;66:8430-8.